Stimulant Reduction Intervention using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a randomized controlled trial

This study is designed to test the effectiveness of a structured, vigorous-intensity exercise program as an augmentation to usual care for individuals with stimulant abuse or dependence.

The **intervention** being tested is:

**Vigorous Intensity High Dose Exercise Augmentation (DEI):** Participants will engage in supervised, one-on-one exercise sessions. The intensity is described as "vigorous," implying a high level of physical exertion. The "high dose" suggests a significant amount of exercise.

The **comparator** is:

**Health Education Intervention Augmentation (HEI):** Participants will receive supervised, one-on-one health education sessions. These sessions are designed to have a similar quantity of visits and contact time as the exercise group, ensuring that any differences in outcomes are more likely due to the specific intervention (exercise vs. health education) rather than just the amount of attention received.

Both groups will also receive **TAU (Treatment As Usual)**, which refers to the standard care provided in the residential treatment setting. The interventions (DEI or HEI) are therefore an *augmentation* to existing treatment.

The **primary outcome measures** are not explicitly detailed in this protocol abstract, but the background section indicates the study aims to examine direct effects on:

Decreased stimulant use

Reduced stimulant craving

The **secondary outcome measures** are also not explicitly detailed, but the background suggests the study will also evaluate improvements in other health domains often affected by stimulant use, including:

Sleep disturbance

Cognitive function

Mood

Weight gain

Quality of life

Anhedonia (inability to feel pleasure)

The study plans to enroll **330 eligible and interested participants**.

The **population** will consist of individuals diagnosed with stimulant abuse or dependence. Participants must be receiving treatment in a residential setting. This implies a population that is actively seeking and engaged in recovery, and likely has a higher severity of stimulant use disorder to warrant residential care.

The **setting** for the study is multisite, meaning it will be conducted across several different residential treatment facilities. This approach helps to ensure the generalizability of the findings across different treatment environments.

As this is a study protocol, the specific instruments and scales intended for use are not detailed in the provided abstract. The protocol states that the study will evaluate outcomes such as decreased stimulant use, reduced craving, sleep disturbance, cognitive function, mood, weight gain, quality of life, and anhedonia.

However, the specific methods for measuring these outcomes (e.g., urine drug screens for stimulant use, specific craving scales, polysomnography or actigraphy for sleep, standardized cognitive tests, mood questionnaires like PHQ-9 or GAD-7, body mass index, quality of life scales like SF-36, or anhedonia scales) are not described in this document. This lack of detail means that for an individual running their own experiment, the exact metrics used by the STRIDE study are not yet known from this protocol.

This study, STRIDE (Stimulant Reduction Intervention using Dosed Exercise), is designed as a **multisite randomized clinical trial (RCT)**. This is considered the gold standard for clinical research because it aims to establish a cause-and-effect relationship between an intervention and an outcome.

**Randomization:** A total of 330 eligible participants who provide informed consent will be randomly assigned to one of two treatment arms:

1. **Vigorous Intensity High Dose Exercise Augmentation (DEI)**

2. **Health Education Intervention Augmentation (HEI)**

Randomization ensures that, on average, the two groups are similar in all characteristics (known and unknown) at the start of the study. This minimizes the risk that any observed differences in outcomes are due to pre-existing differences between the groups rather than the intervention itself. For example, if one group happened to have more severe stimulant dependence or better baseline physical health, randomization helps to balance these factors across both groups.

**Blinding:** The protocol does not explicitly mention blinding. Given the nature of the interventions (supervised exercise vs. supervised health education), it is highly probable that participants will not be blinded to their assigned intervention. They will know whether they are exercising or receiving health education. It is also likely that the staff delivering the interventions will not be blinded. Whether outcome assessors (those measuring stimulant use, craving, mood, etc.) will be blinded to the participants' group assignment is not stated, but this would be a crucial element for minimizing bias if implemented. Without blinding of participants and intervention providers, there's a risk of **performance bias** (participants or providers acting differently due to knowing the intervention) and **detection bias** (outcome assessors interpreting results differently).

**Duration:** The study is structured in two phases:

**Acute Phase:** 12 weeks. During this phase, participants in both arms will attend supervised, one-on-one sessions 3 times per week. This intensive initial period is designed to establish the intervention and observe immediate effects.

**Continuation Phase:** 6 months. Following the acute phase, participants will transition to attending one weekly supervised session for the next six months. This longer phase aims to assess the sustained effects of the intervention and its potential for long-term maintenance of benefits.

The total duration of active intervention and follow-up is approximately 9 months. This extended duration is important for evaluating the long-term impact of exercise on a chronic condition like stimulant dependence, as short-term interventions often show initial benefits that may not persist.

**Statistical Approach:** The protocol abstract does not detail the specific statistical methods that will be used to analyze the data. Typically, an RCT protocol would outline primary and secondary analyses, handling of missing data, and specific statistical tests (e.g., t-tests, ANOVA, regression models, survival analysis). The absence of this detail in the abstract means the specific statistical rigor and power calculations are not described here.

**What this design can and cannot prove:**

**What it *can* prove:** As a randomized controlled trial, if properly executed, this study design has the potential to establish a **causal link** between the vigorous exercise intervention (DEI) and changes in stimulant use, craving, and other health outcomes, compared to the health education intervention (HEI). By randomly assigning participants, the researchers aim to ensure that the only systematic difference between the groups is the intervention received, allowing for stronger conclusions about cause and effect. The multisite nature also enhances the generalizability of findings across different residential treatment settings.

**What it *cannot* prove (based on this protocol):**

* **Mechanism of action:** While the background mentions neurobiological evidence, the protocol itself doesn't detail specific measures to elucidate *how* exercise might be working (e.g., changes in specific neurotransmitters, brain regions, or psychological processes).

* **Effectiveness outside residential settings:** The study is specifically conducted in a residential treatment setting. Its findings may not directly apply to individuals with stimulant abuse or dependence who are in outpatient treatment or not receiving formal treatment.

* **Effectiveness of unsupervised exercise:** The intervention involves supervised sessions. The findings might not generalize to individuals attempting self-directed exercise without professional guidance.

* **Specific dose-response:** While it's "high dose," the protocol doesn't specify varying doses to determine an optimal amount of exercise.

**Major methodological weaknesses (based on this abstract):**

**Lack of blinding:** The probable absence of blinding for participants and intervention providers could introduce performance bias. If outcome assessors are also not blinded, it could lead to detection bias, where their knowledge of group assignment influences their assessment of outcomes.

**Undisclosed specific outcome measures:** The abstract does not specify the exact instruments (e.g., specific drug tests, questionnaires, cognitive batteries) that will be used to measure the primary and secondary outcomes. This makes it difficult to assess the validity and reliability of the planned measurements.

**Undisclosed statistical plan:** The absence of details regarding statistical analysis methods, power calculations, and handling of missing data in the abstract means the rigor of the planned analysis cannot be fully evaluated.

As this is a study protocol published in 2011, it describes the *design* of the study before it was conducted. Therefore, **no results or findings are available yet** from the STRIDE trial in this document. The purpose of a protocol is to outline the methodology and rationale, not to report outcomes.

Since this is a study protocol and no results have been reported, there are **no effect magnitudes** to discuss.

As a study protocol, the primary limitation is that **no actual results or findings are available** from the STRIDE trial. Therefore, the effectiveness of the exercise intervention for stimulant reduction remains unknown based on this document.

Other limitations inherent in the study design, as described in the protocol, include:

**Lack of participant and intervention provider blinding:** Participants will know whether they are in the exercise or health education group, and the staff delivering the interventions will also know. This can introduce **performance bias**, where participants' expectations or providers' enthusiasm might influence outcomes, rather than just the intervention itself.

**Potential for detection bias:** The protocol does not specify if outcome assessors will be blinded. If they are not, their knowledge of group assignment could unconsciously influence their assessment or interpretation of results, particularly for subjective measures like mood or craving.

**Generalizability to non-residential settings:** The study is conducted exclusively in residential treatment settings. This means the findings may not be directly applicable to individuals with stimulant abuse or dependence who are in outpatient programs or attempting recovery independently. The structured, supervised nature of the intervention within a residential setting provides a level of support and control that may not be available elsewhere.

**Focus on augmentation:** The intervention is an "augmentation" to usual care. This means the study will assess the *added benefit* of exercise or health education, rather than comparing exercise to no treatment at all. While clinically relevant, it doesn't isolate the effect of exercise in a vacuum.

**Specificity of "vigorous intensity":** While "vigorous intensity" is specified, the exact parameters (e.g., target heart rate zones, specific types of exercise, duration of vigorous activity within a session) are not detailed in this abstract. This makes it harder to replicate the exact intervention without further information.

**Undisclosed specific outcome measures:** The abstract does not provide details on the specific instruments or methods used to measure stimulant use, craving, sleep, cognition, mood, weight, quality of life, or anhedonia. The validity and reliability of these measures are critical for the study's conclusions.

For someone running their own n=1 experiment, it's important to remember that this is a study *protocol*, so there are no proven results yet. However, based on the rationale and design